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Next-generation sequencing applied either to the entire genome or to a subset,
such as a whole exome, has revolutionized the search for pathogenic mutations in
heritable diseases, including genodermatoses. In this issue, Hosen et al. applied
whole-exome sequencing to identify potential pathogenic mutations in four
candidate genes associated with pseudoxanthoma elasticum, the prototype of
ectopic mineralization disorders. The study highlights the advantages of this
approach over traditional Sanger sequencing, including expedience and cost, but
it also illustrates some of the challenges encountered in implementing this rapidly
evolving technology.
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One of the emerging paradigms of con-
temporary medicine is the concept of
personalized medicine, an approach
that tailors the diagnosis and its manage-
ment to match unique findings in
individual patients. Of course, we have
always practiced personalized medicine
based on an individual’s clinical
presentation and laboratory findings.
However, what makes the concept of
personalized medicine topical at this
juncture is that we now have an
unprecedented capability to decipher
the genetic makeup of each individual
by sequencing an entire genome
or a subset of it, such as a whole exome.
The primary purpose is to find patho-
genic mutations that would explain
phenotypic manifestations in a patient,
but this approach also allows us to
identify sequence variants that may
predispose individuals to late-onset dis-
eases or that may modify the phenotypic
presentation of a primary pathogenic
mutation.
Mutation detection in candidate genes
over the last several decades has pro-
vided new opportunities to manage gen-
odermatoses (Uitto, 2009). Identification
of specific mutations in Mendelian dis-
orders has provided means to confirm the
diagnosis with subclassification, and the
mutation databases have allowed assess-
ment of genotype/phenotype correlations
with long-term prognostication of disease
outcome. Identification of mutations in
families at risk for severe skin diseases has
provided a basis for genetic counseling,
and it has also allowed carrier detection
and presymptomatic testing in diseases
with late onset. Finally, identification of
specific mutations has formed the basis
for prenatal testing and preimplantation
genetic diagnosis, and, importantly, eme-
rging allele-specific treatment approaches
often require precise knowledge about a
mutation.
Until recently, mutation detection in
candidate genes has relied primarily on
Sanger sequencing, which examines
potential candidate genes one at a time.
It has become evident, however, that
several heritable skin diseases have
underlying mutations in different genes,
with resultant phenocopies, and in
many cases attempts to identify candi-
date genes by conventional approaches,
such as positional cloning and homo-
zygosity mapping, have not been suc-
cessful. The landscape of mutation
detection is changing rapidly with gen-
ome-wide, next-generation sequencing
(NGS) approaches that allow global
evaluation of sequence variants in an
individual case.
NGS technologies have revolutio-
nized our ability to survey nucleic acid
base-pair composition in the entire gen-
ome. Just over a decade ago, Sanger
sequencing was the mainstay methodol-
ogy, with a cost of approximately
$1,000 per million base-pairs. Now,
the prospect of an entire human genome
(some 3.2 billion base-pairs) being
sequenced for less than $1,000 is a
reality (Hayden, 2014; Wetterstrand,
2014). Although Sanger sequencing
assays the predominant nucleotide or
nucleotides at a given position from a
pool of DNA, NGS yields sequences
from individual DNA molecules in
massive numbers: Sanger sequencing
can give us the average sequence of
1,000 DNA molecules representing a
single genomic position, whereas NGS
can give us the individual sequence
from each of those 1,000 DNA
molecules or 1,000 molecules each
from different genomic positions.
Technologies of NGS, in various for-
mats and different capabilities and capa-
cities, are available, ranging from
bench-top instruments taking just a few
hours to run to large machines requiring
dedicated laboratory space and weeks
to generate and analyze data (for review
see Metzker (2010). Increasing applica-
tion of NGS technologies to numerous
biological and clinical questions is
driving the cost down, and progress
toward commercial application of
nanopore technology, which has the
potential to revolutionize cost and
output speed even further, is gathering
momentum (Laszlo et al., 2014).
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NGS is not without drawbacks, how-
ever, and the field is continuing to
evolve to address a number of issues.
Costs per base-pair are usually quoted
on the basis of sequencing alone,
whereas DNA isolation, storage, and
preparation can incur significant cost
and capital outlay. In addition, the cost
of labor and expertise associated with
bioinformatics analyses of data should
certainly be considered as part of any
NGS project. Current technologies of
NGS are also inherently error prone
(ranging from 0.1 to 15% compared
with Sanger sequencing at 0.1–1%),
and therefore there is a need to
sequence more than a handful of DNA
molecules from the same genomic posi-
tion to be certain that any variation at
that position is correct. This is called
coverage: 10 DNA molecules corre-
sponding to a single genomic locus is
10x coverage, and when preparing
libraries of DNA molecules simulta-
neously from different loci, coverage is
rarely even. As an example, a 100
average coverage of a 39-exon gene can
give differences between exons that are
orders of magnitude (South et al., 2014).
Careful design and optimization is
required to be confident that all areas
of interest are sequenced with sufficient
confidence to identify all potential
variants (Chilamakuri et al., 2014). The
other problem with such large amounts
of sequence information, in particular
from multiple loci generated by whole-
exome sequencing (WES), is mapping
the individual sequences back to a




10/20/2014). Many algorithms are
designed to map short, 100 bp
sequences back to a large, single
sequence reference genome, and signi-
ficant deviations from this (in particular,
insertions or deletions) are often missed
by current workflows because of repeti-
tive elements within the genome and
within the sequence itself (Li and
Durbin, 2009). Nevertheless, decreas-
ing costs and increasing amounts of
data, and an array of publicly available
analysis tools, such as the Galaxy
platform (Giardine et al., 2005), means
that we will soon see even more
applications of NGS to diagnostic
services (Takeichi et al., 2013).
In this issue, Hosen et al. (Hosen
et al., 2015) have approached the gene-
tic basis of pseudoxanthoma elasticum
(PXE), a heritable multisystem disorder
with skin manifestations, with an
expanded, NGS-based mutation detec-
tion strategy. PXE, an autosomal reces-
sive disease, is the paradigm of ectopic
mineralization disorders affecting the
skin, as well as the eyes and arterial
blood vessels, with considerable morbi-
dity and occasional mortality (Uitto
et al., 2010). The phenotypic presenta-
tion of PXE is quite variable, but the
classic form demonstrates late onset
with slowly progressing tissue involve-
ment and clinical manifestations that
lead to loss of visual acuity and
cardiovascular complications. PXE was
initially shown to be caused by
mutations in the ABCC6 gene, which
encodes a putative efflux transporter,
ABCC6, and it is expressed primarily
in the liver and kidneys. Although the
pathomechanistic details leading from
mutations in ABCC6 to ectopic minera-
lization of peripheral connective tissues
remain to be identified, it is clear that in
the majority of families (over 80%) PXE
is caused by mutations in this gene
(Uitto et al., 2013). The spectrum of
ABCC6 mutations consists of missense
or nonsense mutations, or small inser-
tions and deletions, which result in
frame-shift and premature termination
of translation, as well as of large
gene deletions. However, no definitive
genotype/phenotype correlations have
been discovered, possibly implying the
presence of modifier genes and a role
for environmental and life-style factors
(Pfendner et al., 2007). In addition
to ABCC6, phenotypic presentations
similar to classic PXE have been
encountered in patients with mutations
in ENPP1, a gene that underlies
generalized arterial calcification of
infancy. This disease is often diagnosed
by prenatal ultrasound demonstrating
extensive mineralization of arterial
blood vessels and leading in most
cases to demise during the first year of
life (Nitschke and Rutsch, 2012). In
addition, PXE-like cutaneous findings
have been reported in patients with
mutations in GGCX, a gene encoding
an enzyme involved in the vitamin K
cycle in the liver (Vanakker et al., 2007;
Li et al., 2009). Thus, there is evidence
of genetic heterogeneity resulting in a
spectrum of PXE-like phenotypes.
The investigators in the study by
Hosen et al. (2015) streamlined the
mutation detection strategy in PXE by
exploring NGS in a manner that allows
identification of mutations in many
potential candidate genes, including
ABCC6, ENPP1, GGCX, and VKORC1,
in a single workflow. Their approach
utilized WES, which allows the assess-
ment of B1.5% of the human genome
(some 50 million base-pairs) containing
the protein-coding sequences of about
20,000 genes (Figure 1). By doing so,
they were able to generate a list of
variants specific to each patient, which
can potentially total up to 25,000 single-
nucleotide polymorphisms when
compared with the reference genome
(Bamshad et al., 2011). The prior
knowledge of candidate genes known
to cause PXE, when mutated, and the
types of mutations likely to lead to
pathology no doubt greatly assisted
Clinical Implications
 Next-generation sequencing provides an expedient and cost-effective plat-
form to identify pathogenic mutations in patients with genodermatoses.
 This technology will also assist in identification of modifier genes contribut-
ing to the phenotypic variability of such diseases.
 Identification of specific pathogenic mutations will assist in implementing
personalized medicine, consisting of improved genetic counseling, prog-
nostication of long-term outcome, prenatal testing, and preimplantation
genetic diagnosis, as well as the development of allele-specific treatment
modalities.
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their approach. In this context, it should
be noted that de novo gene hunting
through WES or whole-genome
approaches has disclosed a surprising
number of loss-of-function mutations in
apparently healthy individuals (Tennessen
et al., 2012). This is where basic genetics
has a role and parent–child trios or sib-
pairs will facilitate comparisons to narrow
down variants to a manageable number.
This could possibly be a reason for the
difficulties encountered by Hosen et al.
(2015) to find potential modifiers of the
disease phenotypes that NGS may
ultimately provide for PXE.
The study by Hosen et al. (2015) also
highlights several of the challenges and
pitfalls of WES. For example, although
the overall coverage on the targeted
bases was 37x, the overall sequencing
depth of Z5 reads was highly variable.
Specifically, 93% of the exons in
ABCC6 met these criteria, but only
33% of exons in VKORC1 had the
sequence depth of more than 5 reads.
This required the investigators to resort
to traditional Sanger sequencing for all
exons with a depth of less than 20x.
Also, the importance of preparation of
quality DNA is emphasized by their
finding that, in two patients, coverage
was poor for all four genes tested and
this correlated with the poor overall
sequencing depth of the exome.
Another challenge of NGS relates to
the bioinformatics and particularly to
the ability to call sequence variants
pathogenic. For example, as a rule of
thumb, missense mutations identified in
more than 1% of a population are not
considered to be disease-causing. How-
ever, this does not imply that all nucleo-
tide polymorphisms present in the SNP
database at a frequency of o1% are
disease-causing. In fact, these rare poly-
morphisms constitute the majority of
variation between individuals in larger
populations (Tennessen et al., 2012).
Similarly, some of the SNPs with low
allelic frequency affecting the splice
sites could be considered pathogenic,
yet splicing prediction programs do not
reveal evidence for pathogenicity.
Another shortfall of WES is that it may
not detect large insertions or deletions
that can be searched separately
by multiplex ligation–dependent probe
amplification. However, multiplex
ligation–dependent probe amplification
is not available for many genes, includ-
ing three of the candidate genes in the
study by Hosen et al.
Finally, a critical element in looking
for mutations in cohorts, such as PXE, is
making an accurate clinical diagnosis.
This problem emphasizes the impor-
tance of clinical acumen and adherence
to diagnostic criteria for patients who
may fall into a spectrum of genotypi-
cally and phenotypically overlapping
diseases, as in the case of PXE (Uitto
et al., 2014). Specifically, in the ectopic
Sequence exome fragments
Genomic DNA containing exons (~1.5% sequence)
Genomic DNA fragments
Denature and mix with “baits”
(immobilized exon sequences)
Exome capture-hybridization and
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Figure 1. Schematic presentation of basic principles of whole-exome sequencing. Genomic DNA is first fragmented and denatured, followed by hybridization to
baits containing sequences representing protein-coding exons of B20,000 genes (depicted in red). These exon-containing DNA fragments are eluted from the
baits, processed by techniques depending on the sequencing platform, and sequenced to yield individual DNA fragment sequences or ‘‘reads’’. The sequence
information can be aligned to the reference genome, and alignment variations can be scored to uncover pathogenic mutations.
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mineralization disorders affecting the
skin and arterial vasculature, there are
now as many as half a dozen genes that
can result in presentations often with
overlapping clinical features (Li and
Uitto, 2013). Nevertheless, NGS clearly
provides novel tools and strategies to
identify previously unrecognized candi-
date genes in patients with similar
phenotypic presentations, and refine-
ment of the bioinformatics analyses in
the context of clinical phenotypes may
allow identification of modifier genes
that contribute to the clinical hetero-
geneity of these diseases, including PXE.
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The Double Life of Connexin
Channels: Single Is a Treat
Roberto Bruzzone1,2
Although several genetic diseases are caused by mutations in channels
made by connexin family members, there has been little progress in the
development and validation of therapeutic options. An in vitro study in this issue
of JID suggests that an anti-malarial drug may be beneficial in keratitis-ichthyosis
deafness, a severe conexin channel disease associated with potentially fatal
recurrent infections.
Journal of Investigative Dermatology (2015) 135, 940–943; doi:10.1038/jid.2014.524
Ever since the report of a human genetic
disease linked to connexin mutations
more than 20 years ago, pharmacologi-
cal modulation of this class of channels
has acquired clinical relevance. Con-
nexins are special channels, as they
consist of oligomeric structures, termed
connexons or hemichannels, which can
either dock with cognate hemichannels
to form complete intercellular (gap junc-
tion) channels that provide ionic and
metabolic coupling between adjacent
cells, or function as unpaired connex-
ons, whose physiological role, if any,
remains to be firmly established (Saez
et al., 2003). Of note, dysregulated
hemichannel activity by mutated
connexins has been suspected to have
a pathogenic role in some diseases,
perhaps as a consequence of the
resulting loss of cell integrity (Xu and
Nicholson, 2013; Kelly et al., 2014). In
the current issue of JID by Levit et al.
(2015, this issue) describe the effect of a
molecule approved for anti-malarial
treatment, on some of the most
common Cx26 mutations that cause
keratitis-ichthyosis deafness (KID), a
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